Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Riluzole
Drug ID BADD_D01942
Description A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi.
Indications and Usage For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)
Marketing Status Prescription
ATC Code N07XX02
DrugBank ID DB00740
KEGG ID D00775
MeSH ID D019782
PubChem ID 5070
TTD Drug ID D0H0KB
NDC Product Code 70515-700; 35709-0003; 10094-350; 42291-775; 65129-1011; 63537-0066; 62756-983; 70726-0303; 68462-381; 0378-4145; 62756-538; 67877-286; 69076-200; 65977-0045; 63278-1076; 66039-812; 70510-2201
Synonyms Riluzole | 2-Amino-6-trifluoromethoxybenzothiazole | 2 Amino 6 trifluoromethoxybenzothiazole | Rilutek | RP-54274 | RP 54274 | RP54274 | PK-26124 | PK 26124 | PK26124
Chemical Information
Molecular Formula C8H5F3N2OS
CAS Registry Number 1744-22-5
SMILES C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Prostate cancer16.25.01.001; 21.04.02.002--Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.01.01.003--Not Available
Connective tissue disorder15.06.01.006--Not Available
Embolism24.01.01.009--
Infestation23.09.05.001; 11.09.01.001--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Motor dysfunction17.02.10.004--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Polyp08.01.06.010; 16.02.02.005--Not Available
Blood disorder01.05.01.004--Not Available
Disease progression08.01.03.0380.001364%
Psychotic disorder19.03.01.002--
Pulmonary function test decreased13.19.01.001--Not Available
Pulmonary toxicity22.01.02.007; 12.03.01.0130.006536%Not Available
Hepatobiliary disease09.01.08.003--Not Available
Urine analysis abnormal13.13.02.008--Not Available
Congenital foot malformation15.11.07.002; 03.11.07.002--Not Available
Vulvovaginal mycotic infection21.14.02.004; 11.03.05.004--Not Available
Liver injury12.01.02.003; 09.01.07.022--Not Available
Adverse reaction08.06.01.018--Not Available
Skin mass23.07.04.014--Not Available
Traumatic liver injury09.01.08.010; 12.01.02.008--Not Available
The 13th Page    First    Pre   13 14    Next   Last    Total 14 Pages